JP2003526362A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526362A5
JP2003526362A5 JP2001567304A JP2001567304A JP2003526362A5 JP 2003526362 A5 JP2003526362 A5 JP 2003526362A5 JP 2001567304 A JP2001567304 A JP 2001567304A JP 2001567304 A JP2001567304 A JP 2001567304A JP 2003526362 A5 JP2003526362 A5 JP 2003526362A5
Authority
JP
Japan
Prior art keywords
mva
cell line
cells
grow
vaccinia virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001567304A
Other languages
English (en)
Japanese (ja)
Other versions
JP4759201B2 (ja
JP2003526362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/002703 external-priority patent/WO2001068820A1/en
Publication of JP2003526362A publication Critical patent/JP2003526362A/ja
Publication of JP2003526362A5 publication Critical patent/JP2003526362A5/ja
Application granted granted Critical
Publication of JP4759201B2 publication Critical patent/JP4759201B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001567304A 2000-03-14 2001-03-10 変異ワクシニアウイルスアンカラ(mva)の改変株 Expired - Fee Related JP4759201B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK200000410 2000-03-14
DKPA200000410 2000-03-14
DKPA200000410 2000-03-14
PCT/EP2001/002703 WO2001068820A1 (en) 2000-03-14 2001-03-10 Altered strain of the modified vaccinia virus ankara (mva)

Publications (3)

Publication Number Publication Date
JP2003526362A JP2003526362A (ja) 2003-09-09
JP2003526362A5 true JP2003526362A5 (https=) 2011-01-27
JP4759201B2 JP4759201B2 (ja) 2011-08-31

Family

ID=8159327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001567304A Expired - Fee Related JP4759201B2 (ja) 2000-03-14 2001-03-10 変異ワクシニアウイルスアンカラ(mva)の改変株

Country Status (25)

Country Link
US (1) US6682743B2 (https=)
EP (1) EP1263936B1 (https=)
JP (1) JP4759201B2 (https=)
KR (1) KR100880765B1 (https=)
CN (1) CN1291012C (https=)
AT (1) ATE305030T1 (https=)
AU (1) AU780696B2 (https=)
BR (1) BR0109158A (https=)
CA (1) CA2397675C (https=)
CZ (1) CZ293690B6 (https=)
DE (1) DE60113512T2 (https=)
DK (1) DK1263936T3 (https=)
EE (1) EE05633B1 (https=)
ES (1) ES2249430T3 (https=)
HK (1) HK1052725B (https=)
HU (1) HU228691B1 (https=)
IL (3) IL150736A0 (https=)
MX (1) MXPA02008873A (https=)
NO (1) NO20024246L (https=)
NZ (1) NZ521270A (https=)
PL (1) PL205922B1 (https=)
RU (1) RU2280075C2 (https=)
SI (1) SI1263936T1 (https=)
UA (1) UA84388C2 (https=)
WO (1) WO2001068820A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA76731C2 (uk) * 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
EP1357127A1 (de) * 2002-04-10 2003-10-29 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
CN100540051C (zh) 2002-04-19 2009-09-16 巴法里安诺迪克有限公司 用于接种新生儿的改良的安卡拉痘苗病毒
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
ATE315660T1 (de) * 2002-05-16 2006-02-15 Bavarian Nordic As Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
ES2305514T5 (es) 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
EP2363493B1 (en) 2003-02-20 2012-11-14 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
US7423155B2 (en) 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
DK1536015T3 (da) * 2003-11-24 2008-02-18 Bavarian Nordic As Promotorer til ekspression i modificeret vacciniavirus Ankara
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US7607323B1 (en) 2007-10-16 2009-10-27 Hall Charles F Curl resistant shirt collar and method of fabricating same
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
JP5798124B2 (ja) * 2009-11-20 2015-10-21 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ワクチン構築物におけるポックスウイルスエレメントに関する免疫原性組成物
US9005632B2 (en) 2009-11-20 2015-04-14 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015138471A1 (en) * 2014-03-10 2015-09-17 Arizona Board Of Regents On Behalf Of Arizona State University Heat inactivated poxvirus improves vaccination results
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
NL2014148B1 (en) 2015-01-16 2017-01-05 Univ Erasmus Med Ct Rotterdam Combination vaccine for camelids.
CN115300622A (zh) * 2015-02-25 2022-11-08 纪念斯隆-凯特琳癌症中心 使用灭活的修饰的痘苗病毒安卡拉作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂组合
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3703723A4 (en) 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
EP4519445A2 (en) * 2022-05-04 2025-03-12 University of Maryland, College Park Rna vectors with hairpin-like inserts
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RU2076735C1 (ru) * 1994-03-23 1997-04-10 ГНЦВБ "Вектор" Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
DE69837493T2 (de) * 1997-10-15 2007-12-13 Asahi Kasei Pharma Corp. Verfahren zur qualitätssicherstellung von wässrigen parenteralen lösungen mit thrombomodulin in der lagerung und verteilung
JP3736622B2 (ja) * 2001-06-15 2006-01-18 セイコーエプソン株式会社 ライン駆動回路、電気光学装置及び表示装置

Similar Documents

Publication Publication Date Title
JP2003526362A5 (https=)
CN100335619C (zh) 大规模生产病毒抗原的方法
JP2006527995A5 (https=)
SI1434858T1 (sl) Postopek za pomnoĹľevanje poksvirusa v razmerah brez seruma
Kim et al. Whole-genome sequencing and genetic characteristics of representative porcine reproductive and respiratory syndrome virus (PRRSV) isolates in Korea
WO2003088994A3 (en) Modified vaccinia virus ankara for the vaccination of neonates
KR100908377B1 (ko) 바이러스 증식 방법
CN107190022A (zh) 一种快速构建禽传染性支气管炎病毒反向遗传株的方法
Shi et al. Medium pH between 5.5 and 7.5 has minimal effects on tissue culture of apple
ATE380034T1 (de) Neues verfahren zur herstellung von virus- ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften
Ijaz et al. Establishment of an in vitro regeneration system for genetic transformation of selected sugarcane genotypes
CN107523555A (zh) 获得病毒的方法
CA2372709C (en) Vector for integration of heterologous sequences into poxviral genomes
CN116286685A (zh) 一种基于CRISPR-Cas9技术的表达H9N2禽流感病毒XZ491毒株HA蛋白的重组血清4型禽腺病毒及其制备方法
CN104087549B (zh) 高产杆状病毒的昆虫细胞系及其应用
CN116676274B (zh) 可自失活噬菌体及其制备方法和应用
JP2019511208A5 (https=)
JP2005521423A5 (https=)
RU2009137571A (ru) Способ наращивания рекомбинантного аденовируса человека
JP2019511208A (ja) ウイルスを作製する方法
JP2003500059A5 (https=)
Křižan et al. The effect of media composition on multiplication of grape rootstocks in vitro
CN111642395A (zh) 一种番茄抗病毒突变体的筛选方法
Gangemi et al. Particle heterogeneity in vaccinia virus populations during passage
JP2006509526A (ja) トリ胚性幹細胞上におけるalvacの産生